Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Alnylam Pharmaceuticals reports robust 2022 performance and growth opportunities

Alnylam Pharmaceuticals had a strong financial performance in 2022, driven by the success of AMVUTTRA and advancements in ATTR amyloidosis treatments.
While facing challenges such as FDA requests and the need for self-sustainability, the company is poised for growth with projected revenues and pipeline opportunities.
Opportunities lie in market expansion, innovative pipeline programs, and upcoming regulatory milestones, positioning Alnylam for continued success in RNAi therapeutics.

Alnylam Pharmaceuticals posts robust Q1 growth despite FDA challenges

Alnylam Pharmaceuticals reported strong financial performance in Q1 2023, driven by the TTR franchise and key product sales growth. Despite challenges with the FDA's partial clinical hold, the company remains optimistic about pipeline development and addressing unmet patient needs with RNAi therapeutics.

Alnylam Pharmaceuticals excels in Q2, poised for growth and innovation

Alnylam Pharmaceuticals delivered strong financial results, positive clinical data, and strategic partnerships in Q2 2023, positioning itself for continued growth.
While facing challenges such as market competition and regulatory complexities, Alnylam remains focused on innovation, patient care, and commercial success.
The company's emphasis on R&D, market positioning, and leveraging its RNAi platform underscores its commitment to advancing therapies and driving value for stakeholders.

Alnylam Pharmaceuticals reports robust Q3 growth and eyes HELIOS-B opportunities

Alnylam Pharmaceuticals delivered strong financial results in Q3 2023, showcasing growth and innovation in its product portfolio and pipeline. Despite challenges, the company remains focused on long-term strategies and seizing opportunities in the evolving healthcare landscape.

Alnylam Pharmaceuticals excels in 2023, poised for market leadership

Alnylam Pharmaceuticals demonstrated strong financial performance in 2023, with notable achievements in commercial RNAi therapeutics and franchise growth. The company's strategic focus on innovation, study optimization, and market positioning bodes well for future success and market leadership in RNAi therapeutics.

Alnylam Pharmaceuticals reports robust Q1 performance and strategic readiness

Alnylam Pharmaceuticals showcased strong financial performance, strategic focus on patient needs, and readiness for upcoming milestones.
While facing challenges in meeting guidance and ensuring successful launches, the company is well-positioned for growth and innovation.
Opportunities lie in upcoming milestones, secondary endpoint focus, and future catalysts, driving potential value creation and differentiation.

Alnylam Pharmaceuticals excels in Q2 2024, poised for sustained growth

Alnylam Pharmaceuticals demonstrated strong financial performance and clinical advancements in Q2 2024, driven by key revenue growth drivers and pipeline progress.
While facing challenges such as rising expenses, the company's strategic strengths in franchise performance and margin improvement position it well for future opportunities.
With upcoming milestones and increased guidance, Alnylam is poised to capitalize on growth prospects and maintain its position as a leader in rare disease therapeutics.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2024 on Thursday, May 2, 2024, before the U.S. financial markets open. Management will provide an update on the Company and discuss first quarter 2024 results as well as expectations for the future via conference call on Thursday, May 2, 2024 at 8:30 am ET. To access the call, please r.

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

ALNY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.

NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Levi & Korsinsky Reminds Alnylam Investors of the Ongoing Investigation into Potential Violations of Securities Laws - ALNY

NEW YORK, NY / ACCESSWIRE / April 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Alnylam Pharmaceuticals, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ALNY

NEW YORK, NY / ACCESSWIRE / April 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

ALNY STOCK ALERT: Levi & Korsinsky Notifies Alnylam Pharmaceuticals, Inc. Investors of an Ongoing Investigation

Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick

NEW YORK, NY / ACCESSWIRE / April 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - ALNY

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan). Zilebesiran is an investigational RNAi t.

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

NEW YORK, NY / ACCESSWIRE / March 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Levi & Korsinsky Announces an Investigation on Behalf of Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who May Have Been Affected by Fraud

NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Investors who lost money on Alnylam Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - ALNY

NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Alnylam Being Investigated on Behalf of Alnylam Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.

NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Lost Money on Alnylam Pharmaceuticals, Inc.(ALNY)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

NEW YORK, NY / ACCESSWIRE / March 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Alnylam Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- ALNY

NEW YORK, NY / ACCESSWIRE / March 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Did Alnylam Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate- ALNY

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, at the American College of Cardiology (ACC) Scientific Session on Sunday, April 7, 2024 at 7:00 pm ET. The event will include pr.

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

NEW YORK, NY / ACCESSWIRE / March 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

ALNY ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Alnylam Pharmaceuticals, Inc. Investment

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of the Family Health History Road Trip, its program designed to encourage conversations between family members about their health history so they can discuss with their doctor to better understand their risk for developing an inherited disease like hereditary ATTR (hATTR) amyloidosis. Inspired by the traditional family road trip, the program follows.

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

NEW YORK, NY / ACCESSWIRE / March 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

ALNY ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Alnylam Pharmaceuticals, Inc.

NEW YORK, NY / ACCESSWIRE / March 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders May Have Been Affected by Fraud - Levi & Korsinsky Investigates

NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK, NY / ACCESSWIRE / March 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Alnylam Pharmaceuticals, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ALNY

Alnylam Pharmaceuticals, Inc. (ALNY) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.

Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ:ALNY) concerning possible violations of federal securities laws. On September 13, 2023, Alnylam announced the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) approved Alnylam's application to expand approval for Onpattro to ATTR-cardiomyopathy (CM) patients.

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky, LLP Investigates

Roche Holding AG

Roche and partner Alnylam said on Tuesday their experimental drug against high blood pressure was shown to work when used in combination with the standard of care in a phase 2 trial.

News for Alnylam Pharmaceuticals Stock (ALNY)